Kenneth Cusi, MD, FACP, FACE
Professor Of Medicine
About Kenneth Cusi
Dr. Kenneth Cusi is a Professor of Medicine at the Division of Endocrinology, Diabetes & Metabolism in the Department of Medicine at the University of Florida. He received his medical degree in Argentina from the University of Buenos Aires School of Medicine and is board certified in both Internal Medicine and Endocrinology, Diabetes & Metabolism. He completed his residency at the Center of Medical Education & Clinical Research (CEMIC) in Buenos Aires, Argentina, and a clinical fellowship at Baylor College of Medicine in Houston. Prior to joining the University of Florida, Dr. Cusi was a faculty for over 15 years at the Diabetes Division, University of Texas Health Science Center at San Antonio (UTHSCSA) and the Veterans Health Administration System in Texas; one of the leading diabetes programs in the country. He is a fellow of the American College of Physicians (ACP) and the American Association of Clinical Endocrinologists (AACE). He has actively participated in many clinical diabetes programs and in the training of many young researchers and clinicians. He is the principal investigator in ongoing NIH grants, investigator-initiated as well as multicenter industry-sponsored studies, with a focus on obesity, type 2 diabetes mellitus and nonalcoholic fatty liver disease (NAFLD).
Teaching Profile
Courses Taught
2014-2018
MDT7200 Elect Top/Medicine
2016
MDC7200 Medicine Clerkship
Board Certifications
-
Endocrinology, Diabetes, and MetabolismAmerican Board of Internal Medicine
-
Internal MedicineAmerican Board of Internal Medicine
Clinical Profile
Dr. Cusi brings to his patient care many years of clinical experience and a deep understanding of the pathophysiology and management of endocrinology, diabetes and metabolism. His areas of interest include management of type 2 diabetes and metabolic syndrome, along with its liver-associated complication of nonalcoholic fatty liver disease.
Specialties
- Endocrinology, Diabetes and Metabolism
- Endocrinology, Diabetes and Metabolism
Areas of Interest
- Obesity
- Type 2 diabetes
Research Profile
Dr. Cusi is the principal investigator of a number of ongoing clinical research projects. His grants focus on cutting-edge research in adult endocrinology, diabetes and metabolism, both on clinical and basic research aspects related to the role of obesity and lipotoxicity in the development of Type 2 diabetes and its complications, in particular, the pathogenesis of NAFLD. He has published more than 90 original articles, invited reviews and book chapters in the main journals in the fields of obesity, diabetes and liver disease. Dr. Cusi is a nationally and internationally recognized investigator and speaker on the impact of NAFLD in humans,. His observation in 2006 (NEJM, 2006) that pioglitazone is an effective pharmacological treatment for NASH in people with prediabetes or T2D, confirmed in a 3-year study (Annals Intern Med, 2016), has been incorporated into all major NAFLD guidelines for the management of NAFLD. His current work centers on discovering underlying mechanisms of NAFLD and new treatments. He is an advocate for liver screening in type 2 diabetes and other groups at high-risk groups of cirrhosis from NASH. Most recently involved in the multidisciplinary 2021 AGA consensus statement, 2021 ALEH NAFLD guidance, 2022 AACE NAFLD clinical practice guideline, and 2023 ADA Standards of Care related to NAFLD.
Open Researcher and Contributor ID (ORCID)
0000-0002-8629-418X
Areas of Interest
- Metabolic syndrome
- Non-alcoholic Fatty Liver Disease
- Type 2 Diabetes
Publications
Academic Articles
2025
Addressing the High and Rising Global Burden of Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction‐Associated Steatohepatitis (MASH): From the Growing Prevalence to Payors’ Perspective
Alimentary Pharmacology & Therapeutics.
[DOI] 10.1111/apt.70020.
2025
Decreases in cT1 and liver fat content reflect treatment-induced histological improvements in MASH
Journal of Hepatology.
82(3):438-445
[DOI] 10.1016/j.jhep.2024.08.031.
2025
Erratum: Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: October 2024 updates to AASLD Practice Guidance.
Hepatology (Baltimore, Md.).
[DOI] 10.1097/HEP.0000000000001186.
[PMID] 39937959.
2025
Interdisciplinary perspectives on the co-management of metabolic dysfunction-associated steatotic liver disease and coronary artery disease.
The lancet. Gastroenterology & hepatology.
10(1):82-94
[DOI] 10.1016/S2468-1253(24)00310-8.
[PMID] 39674228.
2025
Letter to the Editor: Serum identification of at-risk MASH: The metabolomics-advanced steatohepatitis fibrosis score (MASEF).
Hepatology (Baltimore, Md.).
81(1):E12-E16
[DOI] 10.1097/HEP.0000000000001061.
[PMID] 39325967.
2025
Pan-PPAR agonist lanifibranor improves insulin resistance and hepatic steatosis in patients with T2D and MASLD
Journal of Hepatology.
[DOI] 10.1016/j.jhep.2024.12.045.
2025
Reply: AASLD Resmetirom Guidance.
Hepatology (Baltimore, Md.).
[DOI] 10.1097/HEP.0000000000001267.
[PMID] 39951255.
2025
Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: October 2024 updates to AASLD Practice Guidance
Hepatology.
81(1):312-320
[DOI] 10.1097/hep.0000000000001112.
2024
A global action agenda for turning the tide on fatty liver disease.
Hepatology (Baltimore, Md.).
79(2):502-523
[DOI] 10.1097/HEP.0000000000000545.
[PMID] 37540183.
2024
A multisociety Delphi consensus statement on new fatty liver disease nomenclature.
Annals of hepatology.
29(1)
[DOI] 10.1016/j.aohep.2023.101133.
[PMID] 37364816.
2024
Artificial intelligence-assisted digital pathology for non-alcoholic steatohepatitis: current status and future directions.
Journal of hepatology.
80(2):335-351
[DOI] 10.1016/j.jhep.2023.10.015.
[PMID] 37879461.
2024
Detecting altered hepatic lipid oxidation by MRI in an animal model of MASLD.
Cell reports. Medicine.
5(9)
[DOI] 10.1016/j.xcrm.2024.101714.
[PMID] 39241774.
2024
From NAFLD to MASLD: Promise and pitfalls of a new definition †.
Hepatology (Baltimore, Md.).
79(2):E13-E15
[DOI] 10.1097/HEP.0000000000000706.
[PMID] 38112428.
2024
From NAFLD to MASLD: Promise and pitfalls of a new definition.
Annals of hepatology.
29(4)
[DOI] 10.1016/j.aohep.2023.101179.
[PMID] 38944463.
2024
From NAFLD to MASLD: Promise and pitfalls of a new definition.
Journal of hepatology.
81(1):e18-e19
[DOI] 10.1016/j.jhep.2023.09.038.
[PMID] 38906626.
2024
Global survey of stigma among physicians and patients with nonalcoholic fatty liver disease
Journal of Hepatology.
80(3):419-430
[DOI] 10.1016/j.jhep.2023.11.004.
2024
Guideline-based management of metabolic dysfunction-associated steatotic liver disease in the primary care setting
Postgraduate Medicine.
136(3):229-245
[DOI] 10.1080/00325481.2024.2325332.
2024
Implementation of a liver health check in people with type 2 diabetes.
The lancet. Gastroenterology & hepatology.
9(1):83-91
[DOI] 10.1016/S2468-1253(23)00270-4.
[PMID] 38070521.
2024
Insulin resistance is an integral feature of MASLD even in the presence of PNPLA3 variants
JHEP Reports.
6(7)
[DOI] 10.1016/j.jhepr.2024.101092.
[PMID] 39022386.
2024
Making Sense of the Nonalcoholic Fatty Liver Disease Clinical Practice Guidelines: What Clinicians Need to Know
Diabetes Spectrum.
37(1):29-38
[DOI] 10.2337/dsi23-0014.
[PMID] 38385100.
2024
Metabolic dysfunction-associated steatohepatitis (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) require urgent attention by primary care physicians and endocrinologists.
Endocrinologia, diabetes y nutricion.
71(4):149-151
[DOI] 10.1016/j.endien.2024.01.007.
[PMID] 38735676.
2024
Nonalcoholic Fatty Liver Disease in Diabetes: A Call to Action
Diabetes Spectrum.
37(1):5-7
[DOI] 10.2337/dsi23-0015.
[PMID] 38385097.
2024
Obesity increases the risk of hepatic fibrosis in young adults with type 2 diabetes mellitus: the need to screen.
Obesity (Silver Spring, Md.).
32(10):1967-1974
[DOI] 10.1002/oby.24130.
[PMID] 39315409.
2024
Pharmacological Approaches to Nonalcoholic Fatty Liver Disease: Current and Future Therapies
Diabetes Spectrum.
37(1):48-58
[DOI] 10.2337/dsi23-0012.
[PMID] 38385098.
2024
Role of Insulin Resistance in the Development of Nonalcoholic Fatty Liver Disease in People With Type 2 Diabetes: From Bench to Patient Care
Diabetes Spectrum.
37(1):20-28
[DOI] 10.2337/dsi23-0013.
[PMID] 38385099.
2024
Selective Agonists of Thyroid Hormone Receptor Beta for the Treatment of NASH.
The New England journal of medicine.
390(6):559-561
[DOI] 10.1056/NEJMe2314365.
[PMID] 38324491.
2024
Serum identification of at-risk MASH: The metabolomics-advanced steatohepatitis fibrosis score (MASEF).
Hepatology (Baltimore, Md.).
79(1):135-148
[DOI] 10.1097/HEP.0000000000000542.
[PMID] 37505221.
2024
The impact of stigma on quality of life and liver disease burden among patients with nonalcoholic fatty liver disease.
JHEP reports : innovation in hepatology.
6(7)
[DOI] 10.1016/j.jhepr.2024.101066.
[PMID] 39022387.
2023
4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes-2023.
Diabetes care.
46(Suppl 1):S49-S67
[DOI] 10.2337/dc23-S004.
[PMID] 36507651.
2023
A global research priority agenda to advance public health responses to fatty liver disease.
Journal of hepatology.
79(3):618-634
[DOI] 10.1016/j.jhep.2023.04.035.
[PMID] 37353401.
2023
A multisociety Delphi consensus statement on new fatty liver disease nomenclature.
Hepatology (Baltimore, Md.).
78(6):1966-1986
[DOI] 10.1097/HEP.0000000000000520.
[PMID] 37363821.
2023
A multisociety Delphi consensus statement on new fatty liver disease nomenclature.
Journal of hepatology.
79(6):1542-1556
[DOI] 10.1016/j.jhep.2023.06.003.
[PMID] 37364790.
2023
A phase I/II study of ARO-HSD, an RNA interference therapeutic, for the treatment of non-alcoholic steatohepatitis
Journal of Hepatology.
78(4):684-692
[DOI] 10.1016/j.jhep.2022.11.025.
2023
A Reduced Pancreatic Polypeptide Response is Associated With New-onset Pancreatogenic Diabetes Versus Type 2 Diabetes
The Journal of Clinical Endocrinology & Metabolism.
108(5):e120-e128
[DOI] 10.1210/clinem/dgac670.
[PMID] 36404274.
2023
Addendum. 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes-2023. Diabetes Care 2023;46(Suppl. 1):S49-S67.
Diabetes care.
46(9):1718-1720
[DOI] 10.2337/dc23-ad09.
[PMID] 37356015.
2023
Adipose Tissue Insulin Resistance Predicts the Severity of Liver Fibrosis in Patients With Type 2 Diabetes and NAFLD
The Journal of Clinical Endocrinology & Metabolism.
108(5):1192-1201
[DOI] 10.1210/clinem/dgac660.
2023
Approach to the Patient With Nonalcoholic Fatty Liver Disease
The Journal of Clinical Endocrinology & Metabolism.
108(2):483-495
[DOI] 10.1210/clinem/dgac624.
2023
Diabetes and cirrhosis: Current concepts on diagnosis and management.
Hepatology (Baltimore, Md.).
77(6):2128-2146
[DOI] 10.1097/HEP.0000000000000263.
[PMID] 36631005.
2023
Erratum. 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes-2023. Diabetes Care 2023;46(Suppl. 1):S49-S67.
Diabetes care.
46(9)
[DOI] 10.2337/dc23-er09a.
[PMID] 37356013.
2023
Evaluation of PXL065 – deuterium-stabilized (R)-pioglitazone in patients with NASH: A phase II randomized placebo-controlled trial (DESTINY-1).
Journal of hepatology.
78(5):914-925
[DOI] 10.1016/j.jhep.2023.02.004.
[PMID] 36804402.
2023
Expert Panel Consensus on Clinical Assertion Statements Describing Noninvasive Tools for Diagnosing Nonalcoholic Steatohepatitis.
Journal of clinical gastroenterology.
57(3):253-264
[DOI] 10.1097/MCG.0000000000001780.
[PMID] 36251413.
2023
Identification of High-Risk Patients With Nonalcoholic Fatty Liver Disease in Endocrinology Clinics.
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
29(11):912-918
[DOI] 10.1016/j.eprac.2023.06.012.
[PMID] 37406857.
2023
Impact of Type 2 Diabetes on the Outcomes of Solid Organ Transplantations in the U.S.: Data From a National Registry.
Diabetes care.
46(12):2162-2170
[DOI] 10.2337/dc23-1085.
[PMID] 37748128.
2023
Introduction and Methodology: Standards of Care in Diabetes-2023.
Diabetes care.
46(Suppl 1):S1-S4
[DOI] 10.2337/dc23-Sint.
[PMID] 36507647.
2023
Measuring NAFLD models of care
Nature Reviews Gastroenterology & Hepatology.
20(10):626-627
[DOI] 10.1038/s41575-023-00798-9.
2023
Metabolic Syndrome and Its Association with Nonalcoholic Steatohepatitis.
Clinics in liver disease.
27(2):187-210
[DOI] 10.1016/j.cld.2023.01.002.
[PMID] 37024202.
2023
Nonalcoholic fatty liver disease (NAFLD) and associated mortality in individuals with type 2 diabetes, pre-diabetes, metabolically unhealthy, and metabolically healthy individuals in the United States.
Metabolism: clinical and experimental.
146
[DOI] 10.1016/j.metabol.2023.155642.
[PMID] 37380016.
2023
Pioglitazone discontinuation in patients with nonalcoholic steatohepatitis is associated with disease recurrence.
Diabetes, obesity & metabolism.
25(4):1112-1116
[DOI] 10.1111/dom.14936.
[PMID] 36495442.
2023
Posttransplant Diabetes Mellitus: Recent Developments in Pharmacological Management of Hyperglycemia
The Journal of Clinical Endocrinology & Metabolism.
109(1):e1-e11
[DOI] 10.1210/clinem/dgad395.
2023
Real-world evidence on non-invasive tests and associated cut-offs used to assess fibrosis in routine clinical practice.
JHEP reports : innovation in hepatology.
5(1)
[DOI] 10.1016/j.jhepr.2022.100596.
[PMID] 36644239.
2023
Research Priorities for Precision Medicine in NAFLD.
Clinics in liver disease.
27(2):535-551
[DOI] 10.1016/j.cld.2023.01.016.
[PMID] 37024222.
2023
Summary of Revisions: Standards of Care in Diabetes-2023.
Diabetes care.
46(Suppl 1):S5-S9
[DOI] 10.2337/dc23-Srev.
[PMID] 36507641.
2023
Validation of a Clinical Risk-based Classification System in a Large Nonalcoholic Fatty Liver Disease Real-world Cohort.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
21(11):2889-2900.e10
[DOI] 10.1016/j.cgh.2023.02.024.
[PMID] 36871772.
2022
A global view of the interplay between non-alcoholic fatty liver disease and diabetes.
The lancet. Diabetes & endocrinology.
10(4):284-296
[DOI] 10.1016/S2213-8587(22)00003-1.
[PMID] 35183303.
2022
A Simple Test to Identify the Risk of NASH and Cirrhosis in People With Obesity or Diabetes: The Time to Screen Is Now
The Journal of Clinical Endocrinology & Metabolism.
107(7):e3076-e3077
[DOI] 10.1210/clinem/dgac186.
[PMID] 35333917.
2022
Abdominal obesity and dsyglycemia are risk factors for liver fibrosis progression in NAFLD subjects: A population-based study.
Frontiers in endocrinology.
13
[DOI] 10.3389/fendo.2022.1051958.
[PMID] 36714592.
2022
Advancing the global public health agenda for NAFLD: a consensus statement.
Nature reviews. Gastroenterology & hepatology.
19(1):60-78
[DOI] 10.1038/s41575-021-00523-4.
[PMID] 34707258.
2022
American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD).
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
28(5):528-562
[DOI] 10.1016/j.eprac.2022.03.010.
[PMID] 35569886.
2022
Are novel glucose-lowering agents’ cardiorenal benefits generalizable to individuals of Black race? A meta-trial sequential analysis to address disparities in cardiovascular and renal outcome trials enrolment.
Diabetes, obesity & metabolism.
24(1):154-159
[DOI] 10.1111/dom.14540.
[PMID] 34472689.
2022
Assessing strategies to target screening for advanced liver fibrosis among overweight and obese patients.
Metabolism and target organ damage.
2
[DOI] 10.20517/mtod.2022.08.
[PMID] 36017449.
2022
Association of Obesity, Diabetes, and Alcohol Use With Liver Fibrosis Among US Adults With Hepatitis C Virus Infection.
JAMA network open.
5(3)
[DOI] 10.1001/jamanetworkopen.2021.42282.
[PMID] 35302636.
2022
Comparable Cardiorenal Benefits of SGLT2 Inhibitors and GLP-1RAs in Asian and White Populations: An Updated Meta-analysis of Results From Randomized Outcome Trials
Diabetes Care.
45(4):1007-1012
[DOI] 10.2337/dc21-1722.
2022
Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial.
The lancet. Diabetes & endocrinology.
10(6):393-406
[DOI] 10.1016/S2213-8587(22)00070-5.
[PMID] 35468325.
2022
Greater ectopic fat deposition and liver fibroinflammation and lower skeletal muscle mass in people with type 2 diabetes.
Obesity (Silver Spring, Md.).
30(6):1231-1238
[DOI] 10.1002/oby.23425.
[PMID] 35475573.
2022
JCL Roundtable. Obesity, Diabetes, and Liver Disease in Relation to Cardiovascular Risk.
Journal of clinical lipidology.
16(2):115-127
[DOI] 10.1016/j.jacl.2022.03.007.
[PMID] 35430025.
2022
Management of NAFLD in primary care settings.
Liver international : official journal of the International Association for the Study of the Liver.
42(11):2377-2389
[DOI] 10.1111/liv.15404.
[PMID] 35986897.
2022
Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles.
Hepatology (Baltimore, Md.).
76(4):1121-1134
[DOI] 10.1002/hep.32427.
[PMID] 35220605.
2022
Noninvasive Diagnosis of Nonalcoholic Steatohepatitis and Advanced Liver Fibrosis Using Machine Learning Methods: Comparative Study With Existing Quantitative Risk Scores.
JMIR medical informatics.
10(6)
[DOI] 10.2196/36997.
[PMID] 35666557.
2022
Reply.
Gastroenterology.
162(7):2132-2134
[DOI] 10.1053/j.gastro.2022.02.019.
[PMID] 35183548.
2022
Response to: “Nonalcoholic fatty liver disease in diabetes: Overlooked or just ignored?”.
Obesity (Silver Spring, Md.).
30(5):971-972
[DOI] 10.1002/oby.23422.
[PMID] 35394120.
2022
The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists for the Management of NAFLD
The Journal of Clinical Endocrinology & Metabolism.
107(1):29-38
[DOI] 10.1210/clinem/dgab578.
[PMID] 34406410.
2021
A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
The New England journal of medicine.
384(12):1113-1124
[DOI] 10.1056/NEJMoa2028395.
[PMID] 33185364.
2021
Advanced Liver Fibrosis Is Common in Patients With Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening
Diabetes Care.
44(2):399-406
[DOI] 10.2337/dc20-1997.
[PMID] 33355256.
2021
Atherogenic dyslipidemia, but not hyperglycemia, is an independent factor associated with liver fibrosis in subjects with type 2 diabetes and NAFLD: a population-based study.
European journal of endocrinology.
184(4):587-596
[DOI] 10.1530/EJE-20-1240.
[PMID] 33606661.
2021
Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease.
Gastroenterology.
161(5):1657-1669
[DOI] 10.1053/j.gastro.2021.07.049.
[PMID] 34602251.
2021
Defining comprehensive models of care for NAFLD
Nature Reviews Gastroenterology & Hepatology.
18(10):717-729
[DOI] 10.1038/s41575-021-00477-7.
2021
Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study.
The lancet. Gastroenterology & hepatology.
6(11):889-902
[DOI] 10.1016/S2468-1253(21)00300-9.
[PMID] 34560015.
2021
Glucagon-Like Peptide 1 Receptor Agonists and Chronic Lower Respiratory Disease Exacerbations Among Patients With Type 2 Diabetes.
Diabetes care.
44(6):1344-1352
[DOI] 10.2337/dc20-1794.
[PMID] 33875487.
2021
Intact Fasting Insulin Identifies Nonalcoholic Fatty Liver Disease in Patients Without Diabetes.
The Journal of clinical endocrinology and metabolism.
106(11):e4360-e4371
[DOI] 10.1210/clinem/dgab417.
[PMID] 34190318.
2021
Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors.
Nature reviews. Gastroenterology & hepatology.
18(1):24-39
[DOI] 10.1038/s41575-020-00366-5.
[PMID] 33093663.
2021
Patient Determinants for Histologic Diagnosis of NAFLD in the Real World: A TARGET-NASH Study.
Hepatology communications.
5(6):938-946
[DOI] 10.1002/hep4.1689.
[PMID] 34141981.
2021
Pharmacodynamic effects of direct AMP kinase activation in humans with insulin resistance and non-alcoholic fatty liver disease: A phase 1b study
Cell Reports Medicine.
2(12)
[DOI] 10.1016/j.xcrm.2021.100474.
[PMID] 35028615.
2021
PPAR-γ-induced changes in visceral fat and adiponectin levels are associated with improvement of steatohepatitis in patients with NASH.
Liver international : official journal of the International Association for the Study of the Liver.
41(11):2659-2670
[DOI] 10.1111/liv.15005.
[PMID] 34219361.
2021
Preparing for the NASH Epidemic: A Call to Action
Diabetes Care.
44(9):2162-2172
[DOI] 10.2337/dci21-0020.
2021
Preparing for the NASH epidemic: A call to action.
Metabolism: clinical and experimental.
122
[DOI] 10.1016/j.metabol.2021.154822.
[PMID] 34289945.
2021
Preparing for the NASH epidemic: A call to action.
Obesity (Silver Spring, Md.).
29(9):1401-1412
[DOI] 10.1002/oby.23250.
[PMID] 34365735.
2021
Preparing for the NASH Epidemic: A Call to Action.
Gastroenterology.
161(3):1030-1042.e8
[DOI] 10.1053/j.gastro.2021.04.074.
[PMID] 34416976.
2021
Real-World Experience With Automated Insulin Pump Technology in Veterans With Type 1 Diabetes.
Federal practitioner : for the health care professionals of the VA, DoD, and PHS.
38(Suppl 4):S4-S8
[DOI] 10.12788/fp.0156.
[PMID] 35136338.
2021
Response to Comment on Albogami et al. Glucagon-Like Peptide-1 Receptor Agonists and Chronic Lower Respiratory Disease Exacerbations Among Patients With Type 2 Diabetes. Diabetes Care 2021;44:1344-1352.
Diabetes care.
44(8)
[DOI] 10.2337/dci21-0024.
[PMID] 34285101.
2021
Saroglitazar, a PPAR-α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial.
Hepatology (Baltimore, Md.).
74(4):1809-1824
[DOI] 10.1002/hep.31843.
[PMID] 33811367.
2021
Severity of metabolic syndrome is greater among nonalcoholic adults with elevated ALT and advanced fibrosis.
Nutrition research (New York, N.Y.).
88:34-43
[DOI] 10.1016/j.nutres.2020.12.023.
[PMID] 33743323.
2021
Severity of non-alcoholic steatohepatitis is not linked to testosterone concentration in patients with type 2 diabetes.
PloS one.
16(6)
[DOI] 10.1371/journal.pone.0251449.
[PMID] 34077443.
2021
Type 2 diabetes mellitus increases the risk of hepatic fibrosis in individuals with obesity and nonalcoholic fatty liver disease.
Obesity (Silver Spring, Md.).
29(11):1950-1960
[DOI] 10.1002/oby.23263.
[PMID] 34553836.
2020
A diabetologist’s perspective of non-alcoholic steatohepatitis (NASH): Knowledge gaps and future directions.
Liver international : official journal of the International Association for the Study of the Liver.
40 Suppl 1:82-88
[DOI] 10.1111/liv.14350.
[PMID] 32077613.
2020
Cardiovascular risk in patients with nonalcoholic fatty liver disease: looking at the liver to shield the heart.
Current opinion in lipidology.
31(6):364-366
[DOI] 10.1097/MOL.0000000000000717.
[PMID] 33149083.
2020
Change in hepatic fat content measured by MRI does not predict treatment-induced histological improvement of steatohepatitis.
Journal of hepatology.
72(3):401-410
[DOI] 10.1016/j.jhep.2019.09.018.
[PMID] 31589891.
2020
Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study.
Journal of hepatology.
72(4):613-626
[DOI] 10.1016/j.jhep.2019.10.023.
[PMID] 31697972.
2020
Latin American Association for the study of the liver (ALEH) practice guidance for the diagnosis and treatment of non-alcoholic fatty liver disease.
Annals of hepatology.
19(6):674-690
[DOI] 10.1016/j.aohep.2020.09.006.
[PMID] 33031970.
2020
Nonalcoholic Fatty Liver Disease: What Does the Primary Care Physician Need to Know?
The American journal of medicine.
133(5):536-543
[DOI] 10.1016/j.amjmed.2020.01.007.
[PMID] 32017891.
2020
Performance of Plasma Biomarkers and Diagnostic Panels for Nonalcoholic Steatohepatitis and Advanced Fibrosis in Patients With Type 2 Diabetes
Diabetes Care.
43(2):290-297
[DOI] 10.2337/dc19-1071.
2020
Relationship between non-alcoholic fatty liver disease during pregnancy and abnormal glucose metabolism during and after pregnancy.
Journal of investigative medicine : the official publication of the American Federation for Clinical Research.
68(3):743-747
[DOI] 10.1136/jim-2019-001186.
[PMID] 31852748.
2020
Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease.
Current diabetes reports.
20(11)
[DOI] 10.1007/s11892-020-01349-1.
[PMID] 33015726.
2020
Semaglutide for the treatment of non-alcoholic steatohepatitis: Trial design and comparison of non-invasive biomarkers.
Contemporary clinical trials.
97
[DOI] 10.1016/j.cct.2020.106174.
[PMID] 33039693.
2020
Targeting pheochromocytoma/paraganglioma with polyamine inhibitors.
Metabolism: clinical and experimental.
110
[DOI] 10.1016/j.metabol.2020.154297.
[PMID] 32562798.
2020
Time to Include Nonalcoholic Steatohepatitis in the Management of Patients With Type 2 Diabetes
Diabetes Care.
43(2):275-279
[DOI] 10.2337/dci19-0064.
2019
Effect of all-extremity high-intensity interval training vs. moderate-intensity continuous training on aerobic fitness in middle-aged and older adults with type 2 diabetes: A randomized controlled trial.
Experimental gerontology.
116:46-53
[DOI] 10.1016/j.exger.2018.12.013.
[PMID] 30576716.
2019
Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes
Diabetes, Obesity and Metabolism.
21(4):812-821
[DOI] 10.1111/dom.13584.
2019
Effect of pioglitazone on bone mineral density in patients with nonalcoholic steatohepatitis: A 36-month clinical trial.
Journal of diabetes.
11(3):223-231
[DOI] 10.1111/1753-0407.12833.
[PMID] 30073778.
2019
From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options.
JHEP reports : innovation in hepatology.
1(4):312-328
[DOI] 10.1016/j.jhepr.2019.07.002.
[PMID] 32039382.
2019
Hepatic enzyme ALT as a marker of glucose abnormality in men with cystic fibrosis.
PloS one.
14(7)
[DOI] 10.1371/journal.pone.0219855.
[PMID] 31318914.
2019
Impact of exenatide on mitochondrial lipid metabolism in mice with nonalcoholic steatohepatitis.
The Journal of endocrinology.
241(3):293-305
[DOI] 10.1530/JOE-19-0007.
[PMID] 31082799.
2019
Incretin-Based Therapies for the Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes.
Hepatology (Baltimore, Md.).
69(6):2318-2322
[DOI] 10.1002/hep.30670.
[PMID] 31006135.
2019
Letter to the Editor: “Hepatic Insulin Extraction in NAFLD Is Related to Insulin Resistance Rather Than Liver Fat Content”.
The Journal of clinical endocrinology and metabolism.
104(11):5249-5250
[DOI] 10.1210/jc.2019-00970.
[PMID] 31225877.
2019
Modulation of Insulin Resistance in Nonalcoholic Fatty Liver Disease.
Hepatology (Baltimore, Md.).
70(2):711-724
[DOI] 10.1002/hep.30429.
[PMID] 30556145.
2019
Neurocognitive Deficits in a Cohort With Class 2 and Class 3 Obesity: Contributions of Type 2 Diabetes and Other Comorbidities.
Obesity (Silver Spring, Md.).
27(7):1099-1106
[DOI] 10.1002/oby.22508.
[PMID] 31116012.
2019
Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies.
The lancet. Diabetes & endocrinology.
7(4):313-324
[DOI] 10.1016/S2213-8587(18)30154-2.
[PMID] 30174213.
2019
Performance of the SteatoTest, ActiTest, NashTest and FibroTest in a multiethnic cohort of patients with type 2 diabetes mellitus.
Journal of investigative medicine : the official publication of the American Federation for Clinical Research.
67(2):303-311
[DOI] 10.1136/jim-2018-000864.
[PMID] 30309884.
2019
Plasma Fibroblast Growth Factor 21 Is Associated With Severity of Nonalcoholic Steatohepatitis in Patients With Obesity and Type 2 Diabetes
The Journal of Clinical Endocrinology & Metabolism.
104(8):3327-3336
[DOI] 10.1210/jc.2018-02414.
[PMID] 30848827.
2019
Re: “Association Between Primary Hypothyroidism and Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis” by Mantovani et al. (Thyroid 2018;28:1270-1284).
Thyroid : official journal of the American Thyroid Association.
29(3)
[DOI] 10.1089/thy.2018.0622.
[PMID] 30652529.
2019
Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial
Diabetes Care.
42(8):1481-1488
[DOI] 10.2337/dc19-0167.
2019
Use of Plasma Fragments of Propeptides of Type III, V, and VI Procollagen for the Detection of Liver Fibrosis in Type 2 Diabetes
Diabetes Care.
42(7):1348-1351
[DOI] 10.2337/dc18-2578.
2018
A Genetic Score Associates With Pioglitazone Response in Patients With Non-alcoholic Steatohepatitis.
Frontiers in pharmacology.
9
[DOI] 10.3389/fphar.2018.00752.
[PMID] 30065651.
2018
Clinical and Histologic Characterization of Nonalcoholic Steatohepatitis in African American Patients
Diabetes Care.
41(1):187-192
[DOI] 10.2337/dc17-1349.
2018
Cytokeratin-18 and enhanced liver fibrosis scores in type 1 and type 2 diabetes and effects of two different insulins.
Journal of investigative medicine : the official publication of the American Federation for Clinical Research.
66(3):661-668
[DOI] 10.1136/jim-2017-000609.
[PMID] 29167192.
2018
Dulaglutide decreases plasma aminotransferases in people with Type 2 diabetes in a pattern consistent with liver fat reduction: a post hoc analysis of the AWARD programme.
Diabetic medicine : a journal of the British Diabetic Association.
35(10):1434-1439
[DOI] 10.1111/dme.13697.
[PMID] 29869810.
2018
Editorial: diabetes, obesity and clinical inertia—the recipe for advanced NASH
Alimentary Pharmacology & Therapeutics.
47(8):1220-1221
[DOI] 10.1111/apt.14473.
2018
Glucagon like peptide-1 receptor agonists for the management of obesity and non-alcoholic fatty liver disease: a novel therapeutic option.
Journal of investigative medicine : the official publication of the American Federation for Clinical Research.
66(1):7-10
[DOI] 10.1136/jim-2017-000554.
[PMID] 28918389.
2018
Pioglitazone for the treatment of NASH in patients with prediabetes or type 2 diabetes mellitus
Gut.
67(7):1371-1371
[DOI] 10.1136/gutjnl-2017-313958.
2018
Pioglitazone improves hepatic mitochondrial function in a mouse model of nonalcoholic steatohepatitis.
American journal of physiology. Endocrinology and metabolism.
315(2):E163-E173
[DOI] 10.1152/ajpendo.00023.2018.
[PMID] 29634314.
2018
Response to Comment on Bril et al. Clinical and Histologic Characterization of Nonalcoholic Steatohepatitis in African American Patients. Diabetes Care 2018;41:187–192
Diabetes Care.
41(9):e137-e138
[DOI] 10.2337/dci18-0026.
2018
Response to Pioglitazone in Patients With Nonalcoholic Steatohepatitis With vs Without Type 2 Diabetes.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
16(4):558-566.e2
[DOI] 10.1016/j.cgh.2017.12.001.
[PMID] 29223443.
2018
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases.
Hepatology (Baltimore, Md.).
67(1):328-357
[DOI] 10.1002/hep.29367.
[PMID] 28714183.
2018
Use of a metabolomic approach to non‐invasively diagnose non‐alcoholic fatty liver disease in patients with type 2 diabetes mellitus
Diabetes, Obesity and Metabolism.
20(7):1702-1709
[DOI] 10.1111/dom.13285.
2017
Concentration-dependent response to pioglitazone in nonalcoholic steatohepatitis.
Alimentary pharmacology & therapeutics.
46(1):56-61
[DOI] 10.1111/apt.14111.
[PMID] 28470881.
2017
Design and rationale for a real-world observational cohort of patients with nonalcoholic fatty liver disease: The TARGET-NASH study
Contemporary Clinical Trials.
61:33-38
[DOI] 10.1016/j.cct.2017.07.015.
2017
Favorable Outcome of Hurthle Cell Carcinoma of the Thyroid Treated With Total Thyroidectomy, Radioiodine, and Selective Use of External-Beam Radiotherapy.
American journal of clinical oncology.
40(4):433-437
[DOI] 10.1097/COC.0000000000000180.
[PMID] 25730603.
2017
Liver fat accumulation as a barometer of insulin responsiveness again points to adipose tissue as the culprit.
Hepatology (Baltimore, Md.).
66(1):296-297
[DOI] 10.1002/hep.29150.
[PMID] 28295426.
2017
Liver Safety of Statins in Prediabetes or T2DM and Nonalcoholic Steatohepatitis: Post Hoc Analysis of a Randomized Trial.
The Journal of clinical endocrinology and metabolism.
102(8):2950-2961
[DOI] 10.1210/jc.2017-00867.
[PMID] 28575232.
2017
Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis.
Annals of internal medicine.
166(3)
[DOI] 10.7326/L16-0629.
[PMID] 28166556.
2017
Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Call to Action.
Diabetes care.
40(3):419-430
[DOI] 10.2337/dc16-1787.
[PMID] 28223446.
2017
Metabolic and histological implications of intrahepatic triglyceride content in nonalcoholic fatty liver disease.
Hepatology (Baltimore, Md.).
65(4):1132-1144
[DOI] 10.1002/hep.28985.
[PMID] 27981615.
2017
Mitochondrial Adaptation in Nonalcoholic Fatty Liver Disease: Novel Mechanisms and Treatment Strategies.
Trends in endocrinology and metabolism: TEM.
28(4):250-260
[DOI] 10.1016/j.tem.2016.11.006.
[PMID] 27986466.
2017
Non-alcoholic fatty liver disease (NAFLD) prevalence and its metabolic associations in patients with type 1 diabetes and type 2 diabetes.
Diabetes, obesity & metabolism.
19(11):1630-1634
[DOI] 10.1111/dom.12973.
[PMID] 28417532.
2017
Nonalcoholic steatohepatitis in nonobese patients: Not so different after all.
Hepatology (Baltimore, Md.).
65(1):4-7
[DOI] 10.1002/hep.28839.
[PMID] 27650699.
2017
Reply to “statins and non-alcoholic steatohepatitis”.
Metabolism: clinical and experimental.
66:e3-e5
[DOI] 10.1016/j.metabol.2016.10.004.
[PMID] 27865560.
2017
The Yin and Yang Between Plasma Glucose Levels and Cortisol Replacement Therapy in Schmidt’s Syndrome.
Journal of investigative medicine high impact case reports.
5(3)
[DOI] 10.1177/2324709617716203.
[PMID] 28748191.
2016
Diabetes medications improve cardiovascular outcomes: the paradigm shifts.
Current opinion in lipidology.
27(6):633-635
[PMID] 27805974.
2016
Different effects of basal insulin peglispro and insulin glargine on liver enzymes and liver fat content in patients with type 1 and type 2 diabetes.
Diabetes, obesity & metabolism.
18 Suppl 2:50-58
[DOI] 10.1111/dom.12751.
[PMID] 27723227.
2016
Hepatic Steatosis and Insulin Resistance, But Not Steatohepatitis, Promote Atherogenic Dyslipidemia in NAFLD.
The Journal of clinical endocrinology and metabolism.
101(2):644-52
[DOI] 10.1210/jc.2015-3111.
[PMID] 26672634.
2016
Lipotoxicity in steatohepatitis occurs despite an increase in tricarboxylic acid cycle activity.
American journal of physiology. Endocrinology and metabolism.
310(7):E484-94
[DOI] 10.1152/ajpendo.00492.2015.
[PMID] 26814015.
2016
Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial.
Annals of internal medicine.
165(5):305-15
[DOI] 10.7326/M15-1774.
[PMID] 27322798.
2016
Metabolic Impact of Nonalcoholic Steatohepatitis in Obese Patients With Type 2 Diabetes.
Diabetes care.
39(4):632-8
[DOI] 10.2337/dc15-1876.
[PMID] 26861926.
2016
Nonalcoholic Fatty Liver Disease: The New Complication of Type 2 Diabetes Mellitus.
Endocrinology and metabolism clinics of North America.
45(4):765-781
[DOI] 10.1016/j.ecl.2016.06.005.
[PMID] 27823604.
2016
Pharmacological management of nonalcoholic fatty liver disease.
Metabolism: clinical and experimental.
65(8):1183-95
[DOI] 10.1016/j.metabol.2016.04.004.
[PMID] 27301803.
2016
Plasma thyroid hormone concentration is associated with hepatic triglyceride content in patients with type 2 diabetes.
Journal of investigative medicine : the official publication of the American Federation for Clinical Research.
64(1):63-8
[DOI] 10.1136/jim-2015-000019.
[PMID] 26755815.
2016
Prediabetes: A Worldwide Epidemic.
Endocrinology and metabolism clinics of North America.
45(4):751-764
[DOI] 10.1016/j.ecl.2016.06.007.
[PMID] 27823603.
2016
Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in patients with Type 2 Diabetes Mellitus.
Clinical diabetes and endocrinology.
2
[DOI] 10.1186/s40842-016-0027-7.
[PMID] 28702244.
2016
Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions.
Diabetologia.
59(6):1112-20
[DOI] 10.1007/s00125-016-3952-1.
[PMID] 27101131.
2015
Clinical value of liver ultrasound for the diagnosis of nonalcoholic fatty liver disease in overweight and obese patients.
Liver international : official journal of the International Association for the Study of the Liver.
35(9):2139-46
[DOI] 10.1111/liv.12840.
[PMID] 25847730.
2015
Cross-talk between branched-chain amino acids and hepatic mitochondria is compromised in nonalcoholic fatty liver disease.
American journal of physiology. Endocrinology and metabolism.
309(4):E311-9
[DOI] 10.1152/ajpendo.00161.2015.
[PMID] 26058864.
2015
High Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels.
The Journal of clinical endocrinology and metabolism.
100(6):2231-8
[DOI] 10.1210/jc.2015-1966.
[PMID] 25885947.
2015
Relationship of Vitamin D With Insulin Resistance and Disease Severity in Non-Alcoholic Steatohepatitis
.
62(2):405-411
2015
Relationship of vitamin D with insulin resistance and disease severity in non-alcoholic steatohepatitis.
Journal of hepatology.
62(2):405-11
[DOI] 10.1016/j.jhep.2014.08.040.
[PMID] 25195551.
2015
Response to do ultrasonographic semiquantitative indices predict histological changes in NASH irrespective of steatosis extent?
Liver international : official journal of the International Association for the Study of the Liver.
35(10):2341-2
[DOI] 10.1111/liv.12869.
[PMID] 25964992.
2015
The role of liver fat and insulin resistance as determinants of plasma aminotransferase elevation in nonalcoholic fatty liver disease.
Hepatology (Baltimore, Md.).
61(1):153-60
[DOI] 10.1002/hep.27395.
[PMID] 25145475.
2015
Therapy and clinical trials.
Current opinion in lipidology.
26(5):472-4
[DOI] 10.1097/MOL.0000000000000225.
[PMID] 26339771.
2014
A validated liquid chromatography tandem mass spectrometry method for simultaneous determination of pioglitazone, hydroxypioglitazone, and ketopioglitazone in human plasma and its application to a clinical study.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
969:219-23
[DOI] 10.1016/j.jchromb.2014.08.019.
[PMID] 25195022.
2014
Healthcare transition from pediatric to adult medical homes in diabetes mellitus.
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
20(7):715-21
[DOI] 10.4158/EP13369.RA.
[PMID] 24449671.
2014
High Prevalence of Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels.
The Journal of clinical endocrinology and metabolism.
100(5)
[DOI] 10.1210/jc.2014-2739.
[PMID] 25303488.
2014
Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease.
Journal of hepatology.
60(1):167-74
[DOI] 10.1016/j.jhep.2013.07.042.
[PMID] 23973932.
2014
Multivariate Analysis of Factors That Influence Improvement in Nonalcoholic Fatty Liver Disease (Nafld) After Pioglitazone Treatment.
Pharmacotherapy.
34(10)
2014
Pharmacodynamic Association of Pioglitazone and Its Active Metabolites With Liver Outcomes Among Patients Diagnosed With Nonalcoholic Steatohepatitis.
Clinical Pharmacology & Therapeutics.
95(1)
2014
Relationship between disease severity, hyperinsulinemia, and impaired insulin clearance in patients with nonalcoholic steatohepatitis.
Hepatology (Baltimore, Md.).
59(6):2178-87
[DOI] 10.1002/hep.26988.
[PMID] 24777953.
2014
The relationship between hepatitis C virus infection and diabetes: time for a divorce?
Hepatology (Baltimore, Md.).
60(4):1121-3
[DOI] 10.1002/hep.27252.
[PMID] 24913680.
2013
Nonalcoholic fatty liver disease: current issues and novel treatment approaches.
Drugs.
73(1):1-14
[DOI] 10.1007/s40265-012-0004-0.
[PMID] 23329465.
2013
Plasma Branch Chain and Aromatic Amino Acid Levels Are Associated With Insulin Resistance in Nonalcoholic Fatty Liver Disease (Nafld)
The FASEB's Journal.
27
2013
The future of thiazolidinedione therapy in the management of type 2 diabetes mellitus.
Current diabetes reports.
13(3):329-41
[DOI] 10.1007/s11892-013-0378-8.
[PMID] 23625197.
2012
Comparison of visceral adipose tissue quantification on water suppressed and nonwater-suppressed MRI at 3.0 Tesla.
Journal of magnetic resonance imaging : JMRI.
35(6):1445-52
[DOI] 10.1002/jmri.23582.
[PMID] 22246813.
2012
Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease.
Hepatology (Baltimore, Md.).
55(5):1389-97
[DOI] 10.1002/hep.25539.
[PMID] 22183689.
2012
Metabolic and Histological Effects of Liver Fat Accumulation in Patients With Nash
Higher Education Policy.
56
2012
Prevalence of prediabetes and diabetes and metabolic profile of patients with nonalcoholic fatty liver disease (NAFLD).
Diabetes care.
35(4):873-8
[DOI] 10.2337/dc11-1849.
[PMID] 22374640.
2012
Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications.
Gastroenterology.
142(4):711-725.e6
[DOI] 10.1053/j.gastro.2012.02.003.
[PMID] 22326434.
2012
The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
The American journal of gastroenterology.
107(6):811-26
[DOI] 10.1038/ajg.2012.128.
[PMID] 22641309.
2012
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
Hepatology (Baltimore, Md.).
55(6):2005-23
[DOI] 10.1002/hep.25762.
[PMID] 22488764.
2012
The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology.
Gastroenterology.
142(7):1592-609
[DOI] 10.1053/j.gastro.2012.04.001.
[PMID] 22656328.
2011
An Endocrine Perspective of Nonalcoholic Fatty Liver Disease (NAFLD).
Therapeutic advances in endocrinology and metabolism.
2(5):211-25
[DOI] 10.1177/2042018811419157.
[PMID] 23148186.
2011
Challenges and opportunities in the management of the Hispanic/Latino patient with type 2 diabetes mellitus. Introduction.
The American journal of medicine.
124(10 Suppl)
[DOI] 10.1016/j.amjmed.2011.07.016.
[PMID] 21939792.
2011
Comment on: Hoeg et al. Lipid-induced insulin resistance affects women less than men and is not accompanied by inflammation or impaired proximal insulin signaling. Diabetes 2011;60:64-73.
Diabetes.
60(9)
[DOI] 10.2337/db11-0687.
[PMID] 21868787.
2011
Focus On the Type 2 Diabetes Patient With Liver Disease: Emphasis On Nonalcoholic Fatty Liver Disease (Nafld)
Endocrine Practice.
17:9-13
2011
Focus On Type 2 Diabetes Comorbidities: Using Incretin-Based Therapies in Patients With Renal, Cardiovascular, and Hepatic Insufficiencies Introduction
Endocrine Practice.
17:3-4
2011
Insulin sensitizers in nonalcoholic steatohepatitis.
Hepatology (Baltimore, Md.).
53(4):1404-5; author reply 1405
[DOI] 10.1002/hep.24179.
[PMID] 21480350.
2011
Metabolic factors in the development of hepatic steatosis and altered mitochondrial gene expression in vivo.
Metabolism: clinical and experimental.
60(8):1090-9
[DOI] 10.1016/j.metabol.2010.12.001.
[PMID] 21310443.
2011
Role of ethnicity in overweight and obese patients with nonalcoholic steatohepatitis.
Hepatology (Baltimore, Md.).
54(3):837-45
[DOI] 10.1002/hep.24483.
[PMID] 21674556.
2011
Unmet needs in Hispanic/Latino patients with type 2 diabetes mellitus.
The American journal of medicine.
124(10 Suppl):S2-9
[DOI] 10.1016/j.amjmed.2011.07.017.
[PMID] 21939795.
2010
Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials.
American journal of cardiovascular drugs : drugs, devices, and other interventions.
10(2):73-84
[DOI] 10.2165/10061630-000000000-00000.
[PMID] 20136164.
2010
Elevated plasma free fatty acids increase cardiovascular risk by inducing plasma biomarkers of endothelial activation, myeloperoxidase and PAI-1 in healthy subjects.
Cardiovascular diabetology.
9
[DOI] 10.1186/1475-2840-9-9.
[PMID] 20158910.
2010
Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome.
The Journal of clinical endocrinology and metabolism.
95(2):829-36
[DOI] 10.1210/jc.2009-1487.
[PMID] 20061429.
2010
Pioglitazone improvement of fasting and postprandial hyperglycaemia in Mexican-American patients with Type 2 diabetes: a double tracer OGTT study.
Clinical endocrinology.
73(3):339-45
[DOI] 10.1111/j.1365-2265.2010.03811.x.
[PMID] 20455891.
2010
The role of adipose tissue and lipotoxicity in the pathogenesis of type 2 diabetes.
Current diabetes reports.
10(4):306-15
[DOI] 10.1007/s11892-010-0122-6.
[PMID] 20556549.
2009
Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis.
Hepatology (Baltimore, Md.).
50(4):1087-93
[DOI] 10.1002/hep.23116.
[PMID] 19670459.
2009
Lessons learned from studying families genetically predisposed to type 2 diabetes mellitus.
Current diabetes reports.
9(3):200-7
[PMID] 19490821.
2009
New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD).
Annals of medicine.
41(4):265-78
[DOI] 10.1080/07853890802552437.
[PMID] 19353360.
2009
Nonalcoholic fatty liver disease in type 2 diabetes mellitus.
Current opinion in endocrinology, diabetes, and obesity.
16(2):141-9
[DOI] 10.1097/MED.0b013e3283293015.
[PMID] 19262374.
2009
Role of insulin resistance and lipotoxicity in non-alcoholic steatohepatitis.
Clinics in liver disease.
13(4):545-63
[DOI] 10.1016/j.cld.2009.07.009.
[PMID] 19818304.
2009
Thiazolidinediones in NASH. An odd couple meant to be?
Journal of clinical gastroenterology.
43(6):503-5
[DOI] 10.1097/MCG.0b013e3181a15e51.
[PMID] 19384246.
2008
Addition of pioglitazone and ramipril to intensive insulin therapy in type 2 diabetic patients improves vascular dysfunction by different mechanisms.
Diabetes care.
31(1):121-7
[PMID] 17909084.
2008
Allergic skin reaction to insulin detemir: resolution with continued use.
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
14(6):796-7
[PMID] 18996804.
2008
Chronic low-dose lipid infusion in healthy patients induces markers of endothelial activation independent of its metabolic effects.
Journal of the cardiometabolic syndrome.
3(3):141-6
[DOI] 10.1111/j.1559-4572.2008.00013.x.
[PMID] 18983329.
2008
Insulin-resistant muscle is exercise resistant: evidence for reduced response of nuclear-encoded mitochondrial genes to exercise.
American journal of physiology. Endocrinology and metabolism.
294(3):E607-14
[DOI] 10.1152/ajpendo.00729.2007.
[PMID] 18182465.
2007
Contrast-enhanced first-pass myocardial perfusion magnetic resonance imaging with parallel acquisition at 3.0 Tesla.
Investigative radiology.
42(6):352-60
[PMID] 17507805.
2007
Effects on insulin secretion and insulin action of a 48-h reduction of plasma free fatty acids with acipimox in nondiabetic subjects genetically predisposed to type 2 diabetes.
American journal of physiology. Endocrinology and metabolism.
292(6):E1775-81
[PMID] 17299078.
2007
Pioglitazone treatment increases whole body fat but not total body water in patients with non-alcoholic steatohepatitis.
Journal of hepatology.
47(4):565-70
[PMID] 17560678.
2007
Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects.
Gastroenterology.
133(2):496-506
[PMID] 17681171.
2007
The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients.
The Journal of clinical endocrinology and metabolism.
92(4):1249-55
[PMID] 17244786.
2007
The role of fenofibrate in clinical practice.
Diabetes & vascular disease research.
4 Suppl 3:S15-20
[PMID] 17935056.
2006
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.
The New England journal of medicine.
355(22):2297-307
[PMID] 17135584.
2006
Exercise-induced improvement in vasodilatory function accompanies increased insulin sensitivity in obesity and type 2 diabetes mellitus.
The Journal of clinical endocrinology and metabolism.
91(12):4903-10
[PMID] 17018657.
2006
First-pass contrast-enhanced myocardial perfusion MRI using a maximum up-slope parametric map.
IEEE transactions on information technology in biomedicine : a publication of the IEEE Engineering in Medicine and Biology Society.
10(3):574-80
[PMID] 16871727.
2006
Reduction in hematocrit level after pioglitazone treatment is correlated with decreased plasma free testosterone level, not hemodilution, in women with polycystic ovary syndrome.
Clinical pharmacology and therapeutics.
80(2):105-14
[PMID] 16890572.
2005
Dose-response effect of elevated plasma free fatty acid on insulin signaling.
Diabetes.
54(6):1640-8
[PMID] 15919784.
2005
Lipid infusion decreases the expression of nuclear encoded mitochondrial genes and increases the expression of extracellular matrix genes in human skeletal muscle.
The Journal of biological chemistry.
280(11):10290-7
[PMID] 15598661.
2004
Discordant effects of a chronic physiological increase in plasma FFA on insulin signaling in healthy subjects with or without a family history of type 2 diabetes.
American journal of physiology. Endocrinology and metabolism.
287(3):E537-46
[PMID] 15126243.
2004
Sustained reduction in plasma free fatty acid concentration improves insulin action without altering plasma adipocytokine levels in subjects with strong family history of type 2 diabetes.
The Journal of clinical endocrinology and metabolism.
89(9):4649-55
[PMID] 15356076.
2003
A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes.
Diabetes.
52(10):2461-74
[PMID] 14514628.
2003
Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: Potential role of PGC1 and NRF1.
Proceedings of the National Academy of Sciences of the United States of America.
100(14):8466-71
[PMID] 12832613.
2002
Effect of IGF-I on FFA and glucose metabolism in control and type 2 diabetic subjects.
American journal of physiology. Endocrinology and metabolism.
282(6):E1360-8
[PMID] 12006367.
2002
Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients.
The Journal of clinical endocrinology and metabolism.
87(6):2784-91
[PMID] 12050251.
2002
Free fatty acid-induced peripheral insulin resistance augments splanchnic glucose uptake in healthy humans.
American journal of physiology. Endocrinology and metabolism.
283(2):E346-52
[PMID] 12110541.
2002
Free fatty acids reduce splanchnic and peripheral glucose uptake in patients with type 2 diabetes.
Diabetes.
51(10):3043-8
[PMID] 12351445.
2002
Normalization of plasma glucose concentration by insulin therapy improves insulin-stimulated glycogen synthesis in type 2 diabetes.
Diabetes.
51(2):462-8
[PMID] 11812756.
2001
Exercise increases hexokinase II mRNA, but not activity in obesity and type 2 diabetes.
Metabolism: clinical and experimental.
50(5):602-6
[PMID] 11319725.
2001
Physiological hyperinsulinemia impairs insulin-stimulated glycogen synthase activity and glycogen synthesis.
American journal of physiology. Endocrinology and metabolism.
280(5):E712-9
[PMID] 11287353.
1995
Regulation of hexokinase II and glycogen synthase mRNA, protein, and activity in human muscle.
The American journal of physiology.
269(4 Pt 1):E701-8
[PMID] 7485484.
Grants
Mar 2024
ACTIVE
WISE II – Obesity and Type-2 Diabetes: Bariatric Surgery Effects on Brain Function
Role: Co-Investigator
Funding: NATL INST OF HLTH NIDDK
Dec 2023
ACTIVE
A Phase 3, randomized, bouble-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus.
Role: Principal Investigator
Funding: BOEHRINGER INGELHEIM PHARM INC
Dec 2023
ACTIVE
A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus
Role: Principal Investigator
Funding: BOEHRINGER INGELHEIM PHARM INC
Dec 2021
– Dec 2022
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing
the Efficacy and Safety of Tirzepatide versus Placebo in Patients with Nonalcoholic Steatohepatitis (NASH)
Role: Principal Investigator
Funding: ELI LILLY AND CO
Sep 2020
ACTIVE
U-01 CONSORTIUM FOR THE STUDY OF CHRONIC PANCREATITIS,DIABETES AND PANCREATIC CANCER CLINICAL CENTERS
Role: Principal Investigator
Funding: NATL INST OF HLTH NIDDK
Jul 2020
– May 2024
Esterase-Sensitive Hyperpolarized 13C Probes for Simultaneous Imaging of pH and Energy Metabolism
Role: Co-Investigator
Funding: NATL INST OF HLTH NIBIB
May 2020
– Feb 2025
Role of Screening and Early Intervention in Primary Care with Low-Dose Pioglitazone for Patients with T2DM and NASH
Role: Principal Investigator
Funding: NATL INST OF HLTH NIDDK
Jul 2019
– Aug 2022
A randomized, double-blind, placebo-controlled, parallel group trial to assess the efficacy and safety of PXL770 versus placebo after 12 weeks of treatment in patients with Nonalcoholic Fatty Liver Disease (NAFLD) with or without type 2 diabetes mellitus
Role: Principal Investigator
Funding: MEDPACE
via POXEL SA
Mar 2019
– Nov 2024
Novel pathways in the pathogenesis and pathophysiology of NAFLD in Hispanics
Role: Co-Investigator
Funding: OHIO UNIV
via NATL INST OF HLTH NIMHD
Sep 2018
– Aug 2020
Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer: Coordinating and Data Management Center (CSCPDPC-CDMC) NOD Study
Role: Principal Investigator
Funding: UNIV OF TEXAS MD ANDERSON CANCER CENTER
via NATL INST OF HLTH NIDDK
Jun 2018
– Mar 2023
Developing a VCTE-based Screening Model for Patients with Type 2 Diabetes and Advanced Fibrosis
Role: Principal Investigator
Funding: ECHOSENS
Apr 2018
ACTIVE
Efficacy, Safety and Mechanism of Action of lanifibranor (IVA337) in patients with Type 2 Diabetes (T2DM) and Nonalcoholic Fatty Ivier disease (NAFLD)
Role: Principal Investigator
Funding: INVENTIVA PHARMA
Dec 2017
– May 2021
Miscellaneous Donors Project
Role: Principal Investigator
Funding: MISCELLANEOUS DONORS
Jun 2017
– Dec 2020
A Phase 2, prospective, multi-center, double-blind, randomized study of Saroglitazar Magnesium, 1 mg, 2 mg, or 4 mg versus placebo in patients with non-alcoholic fatty liver disease (NAFLD) and/or non-alcoholic steatohepatitis (NASH).
Role: Principal Investigator
Funding: PAREXEL INTERNATIONAL PTY
Mar 2017
– Mar 2022
Investigation of efficacy and safety of three dose levels of subcutaneous semaglutide once daily versus placebo in subjects with non-alcoholic steatohepatitis (NASH). A 72-week randomised, double-blind, placebo-controlled, six-armed parallel group, multi-centre, multinational trial
Role: Principal Investigator
Funding: NOVO NORDISK
Oct 2016
– Oct 2021
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602K in Patients with NASH
Role: Principal Investigator
Funding: CIRIUS THERAPEUTICS
via CIRIUS THERAPEUTICS
Oct 2016
ACTIVE
5-year longitudinal observational study of patients with non-alcoholic fatty liver disease or non-alcoholic steatohepatitis.
Role: Principal Investigator
Funding: TARGET PHARMASOLUTIONS dba TARGET RWE
Sep 2016
– Aug 2020
Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer: Coordinating and Data Management Center (CSCPDPC-CDMC)
Role: Principal Investigator
Funding: UNIV OF TEXAS MD ANDERSON CANCER CENTER
via NATL INST OF HLTH NIDDK
Aug 2016
– Jan 2020
A randomized, patient and investigator blinded, placebo-controlled, multicenter study to assess the safety, tolerability, pharmacokinetics and efficacy of LMB763 in patients with non-alcoholic steatohepatitis (NASH)
Role: Principal Investigator
Funding: NOVARTIS PHARMACEUTICALS CORP
Jul 2016
– Jun 2022
Imaging Hepatic Gluconeogenesis with Hyperpolarized Dihydroxyacetone
Role: Co-Investigator
Funding: NATL INST OF HLTH NIDDK
May 2016
– Sep 2017
Developing a Novel Screening Strategy in Overweight & Obese Children at Risk for Non-Alcoholic Fatty Liver Disease (NAFLD)
Role: Other
Funding: ENDOCRINE FELLOWS FOU
Sep 2015
– Dec 2018
Endothelial Dysfunction in Older Adults with Type 2 Diabetes: Effect of Exercise
Role: Project Manager
Funding: NATL INST OF HLTH NIA
Sep 2015
– Aug 2020
U-01 CONSORTIUM FOR THE STUDY OF CHRONIC PANCREATITIS,DIABETES AND PANCREATIC CANCER CLINICAL CENTERS
Role: Co-Investigator
Funding: NATL INST OF HLTH NIDDK
May 2015
ACTIVE
214 CT OPERATING ACCOUNT
Role: Principal Investigator
Funding: UNIV OF FLORIDA
May 2015
ACTIVE
CUSI PI 214 PAYROLL ACCOUNT
Role: Principal Investigator
Funding: UNIV OF FLORIDA
Jan 2015
– Jun 2016
Closing the Care Gap: an Interdisciplinary Approach to Post-fracture Care
Role: Project Manager
Funding: *SHANDS TEACHING HOSPITAL HEALTHCARE
Jun 2014
– May 2022
Obesity and Type-2 Diabetes: Bariatric Surgery Effects on Brain Function
Role: Co-Investigator
Funding: NATL INST OF HLTH NIDDK
Mar 2014
– Mar 2017
A Double-Blind, Placebo-Controlled, Randomized, Parallel Groups, Multicenter Study to Investigate the Effects of Canagliflozin on Insulin Sensitivity, Hepatic Fat Content and Beta Cell Function in Subjects with Type 2 Diabetes Mellitus
Role: Principal Investigator
Funding: JANSSEN RESEARCH AND DEVELOPMENT
Feb 2014
– Sep 2017
A Double-Blind, Placebo-Controlled, Randomized, Parallel Groups, Multicenter Study to Investigate the Effects of Canagliflozin on Insulin Sensitivity, Hepatic Fat Content and the Beta Cell Function in Subjects with Type 2 Diabetes Mellitus
Role: Principal Investigator
Funding: JANSSEN RESEARCH AND DEVELOPMENT
Jan 2013
– Mar 2016
IPA For Nishanth Sunny
Role: Principal Investigator
Funding: US DEPT OF VET AFF GAINESVILLE MED CTR
Sep 2012
– Jan 2016
IPA for Diane Biernacki
Role: Principal Investigator
Funding: US DEPT OF VETERANS AFFAIRS
Education
Fellowship – Endocrinology, Diabetes and Metabolism
1992
·
Baylor University
Medical Degree
1984
·
Universidad de Buenos Aires
Contact Details
Phones:
- Business:
- (352) 273-8662
Emails:
- Business:
- kcusi@ufl.edu
Addresses:
- Business Mailing:
-
PO Box 100226
GAINESVILLE FL 32610 - Business Street:
-
PO Box 100226
GAINESVILLE FL 32610